title: Treatment of Mild Camptocormia with Selegiline in Patients with Parkinson's Disease.
abstract: Camptocormia in Parkinson's disease (PD) is unresponsive to various therapies and induced difficulties in their day-to-day life.
  
  
  
  This study, an open trial, was aimed at assessing the efficacy of selegiline in the treatment of mild camptocormia in PD patients.
  
  
  
  Participants were administered 5 mg of selegiline for the first 8 weeks and 7.5 mg for the second 8 weeks.
  
  
  
  As primary endpoints, the degree of thoracolumbar anteflexion decreased from 23.2° (mean) (11.8° (SD)) at baseline to 18.3° (7.1°) at 16 weeks, and the area of postural sway measured using a Gravicorder increased. However, the differences were not significant. Thoracolumbar anteflexion improved in 60% of the participants.
  
  
  
  In this study, 60% of the participants showed an improvement in anteflexion of the thoracolumbar spine with selegiline, but the change in the degree of anteflexion was 5°, which was not statistically significant. Participants with significant improvement in thoracolumbar anteflexion had an increased postural sway. This change was induced by a decrease in truncal muscle tonus or change in the center of gravity. This study combined the study of anteflexion and stability, and provides information on the treatment of short-term or mild camptocormia.
authors.affiliation: Department of Neurology, Juntendo University Koshigaya Hospital, Saitama, Japan.
authors.forename: Asako
authors.initials: A
authors.lastname: Yoritaka
authors.forename: Hideo
authors.initials: H
authors.lastname: Mori
authors.forename: Nobutaka
authors.initials: N
authors.lastname: Hattori
mesh_terms: D000368:Aged; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009134:Muscular Atrophy, Spinal / Q000150:complications / Q000188:drug therapy*; D010300:Parkinson Disease / Q000150:complications / Q000188:drug therapy*; D012642:Selegiline / Q000627:therapeutic use*; D013121:Spinal Curvatures / Q000150:complications / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000978:Antiparkinson Agents; D012642:Selegiline